Vytrus Biotech (FRA:V5P) EBIT: €3.18 Mil (TTM As of Dec. 2025)


FRA:V5P Vytrus Biotech SA FRA:V5P
63 GF Score
Price €16.70
GF Value €6.81
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech EBIT?

Vytrus Biotech FRA:V5P -2.34% 63 EBIT is €3.18 Mil as of Dec. 2025. GuruFocus rates FRA:V5P with a GF Score™ of 63/100 and a GF Value™ of €6.81 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Vytrus Biotech's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €1.53 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €3.18 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vytrus Biotech's annualized ROC % for the quarter that ended in Dec. 2025 was 30.08%. Vytrus Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 165.11%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vytrus Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 2.45%.

Vytrus Biotech  (FRA:V5P) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vytrus Biotech's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=3.092 * ( 1 - 4.34% )/( (9.013 + 10.652)/ 2 )
=2.9578072/9.8325
=30.08 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13.17 - 0.871 - ( 3.286 - max(0, 1.693 - 5.221+3.286))
=9.013

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14.663 - 0.634 - ( 3.377 - max(0, 1.777 - 5.389+3.377))
=10.652

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Vytrus Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3.062/( ( (1.072 + max(0.683, 0)) + (1.681 + max(0.273, 0)) )/ 2 )
=3.062/( ( 1.755 + 1.954 )/ 2 )
=3.062/1.8545
=165.11 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.316 + 0.493 + 0.018000000000001) - (0.871 + 0 + 0.273)
=0.683

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.982 + 0.623 + 0.015000000000001) - (0.634 + 0 + 0.713)
=0.273

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vytrus Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=3.182/130.134
=2.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech EBIT Related Terms

Vytrus Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Vytrus Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech EBIT Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 0.43 0.65 0.45 1.01 3.18

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.53 0.48 1.65 1.53

FRA:V5P vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Vytrus Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vytrus Biotech EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vytrus Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vytrus Biotech's EV-to-EBIT falls into.


FRA:V5P
63GF Score
Vytrus Biotech SA FRA:V5P
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vytrus Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €3.18 Mil mean?
Vytrus Biotech (FRA:V5P) has a EBIT of €3.18 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vytrus Biotech.
Is Vytrus Biotech's EBIT too high?
Vytrus Biotech's current EBIT is €3.18 Mil. Overall, Vytrus Biotech has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's EBIT compare to VRTX and REGN?
Vytrus Biotech's EBIT of €3.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vytrus Biotech. Vytrus Biotech's current EBIT is €3.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (FRA:V5P) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.81, compared to a current price of €16.70 — trading 145.2% above its estimated fair value. The current EBIT is €3.18 Mil. Vytrus Biotech's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Vytrus Biotech (FRA:V5P), the current EBIT is €3.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (FRA:V5P) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €16.70 is trading 145.2% above its estimated GF Value™ of €6.81. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for FRA:V5P:

  • EBIT: €3.18 Mil
  • GF Value™: €6.81 vs. price of €16.70 (145.2% above fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the FRA:V5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges VYT:Spain
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
63GF Score

Get the complete analysis for FRA:V5P

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.70
Price
€6.81
GF Value